Day: July 2, 2013

The monoclonal antibody revolution

Generic entry for small molecule drugs is controlled by Hatch-Waxman, allowing generic entry 10 – 20 years after FDA approval. For monoclonal antibodies and other

READ MORE
Subscribe

Email Address*